Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China
Background: For multiple myeloma (MM), the proportions of patients reaching the subsequent line of therapy (LOT) decline gradually and real-world data describing the attrition rates of LOT in Chinese MM were limited. Herein, we investigated the attrition rates by subsequent LOTs and their relevant r...
Saved in:
Main Authors: | Wenjiao Tang (Author), Jinrong Yang (Author), Yan Li (Author), Li Zhang (Author), He Li (Author), Jie Wang (Author), Yi Liao (Author), Chunlan Zhang (Author), Ying Qu (Author), Yuhuan Zheng (Author), Ting Niu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Minimal residual disease in multiple myeloma: current status
by: Hong Ding, et al.
Published: (2021) -
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019) -
Real-world assessment of treatment multiple myeloma patients on the example of one hematology center
by: A. S. Luchinin, et al.
Published: (2023) -
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary
by: Szilvia Lovas, et al.
Published: (2022) -
Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials
by: Rana Jreich, et al.
Published: (2024)